Evaluation of Microscopic Hematuria in High-Risk Patients

Risk Stratification

• The American Urological Association (AUA) recommends that a 60-year-old man with a prior smoking history and microscopic hematuria should undergo a complete urologic evaluation including cystoscopy and upper tract imaging due to his high-risk status for urologic malignancy 1
• Age ≥60 years is considered a high-risk factor for urologic malignancy, according to the American Urological Association (AUA) guidelines 1
• Prior smoking history is a risk factor for urologic malignancy, with severity depending on pack-years, as stated by the American Family Physician 1
• Male sex is associated with a higher prevalence of significant urologic disease, as reported by the American Family Physician 2, 3
• The prevalence of asymptomatic microscopic hematuria in older men can be as high as 21%, with a higher risk for significant urologic disease compared to other populations, according to the American Family Physician 3

Definition of Microscopic Hematuria

• Microscopic hematuria is defined as ≥3 red blood cells per high-power field (RBC/HPF) on microscopic evaluation of urinary sediment from 2 of 3 properly collected specimens, as defined by the American Family Physician 3
• Dipstick positivity should always be confirmed with microscopic evaluation due to limited specificity (65-99%), as recommended by the American Family Physician 3, 4
• For high-risk patients, a single urinalysis with ≥3 RBC/HPF may warrant full evaluation, according to the American Family Physician 2

Recommended Evaluation

• The American Family Physician recommends excluding benign causes (exercise, sexual activity, viral illness, trauma, infection) in the initial assessment of microscopic hematuria 5
• The American Family Physician suggests assessing for signs of primary renal disease, including significant proteinuria 2, dysmorphic red blood cells or red cell casts 5, and elevated serum creatinine 5
• Multiphasic CT urography is preferred to identify hydronephrosis, urinary calculi, and renal/ureteral lesions in high-risk patients, as recommended by the American Urological Association (AUA) 1
• Cystoscopy is recommended to evaluate for bladder masses, urethral stricture disease, and benign prostatic hyperplasia in high-risk patients, according to the American Urological Association (AUA) 1
• Urinalysis with microscopic examination, renal function tests, and assessment of inflammatory parameters are recommended as part of the laboratory testing for microscopic hematuria, as stated by the American Family Physician 3, 5
• Urine cytology may be considered if there are risk factors for carcinoma in situ or irritative voiding symptoms, as suggested by the American Urological Association (AUA) 1
• Referral to nephrology is recommended if there are signs of renal parenchymal disease, according to the American Family Physician 5

Risk Factors for Urologic Malignancy

• Age ≥60 years is a high-risk factor for urologic malignancy, as stated by the American Urological Association (AUA) 1
• Smoking history is a risk factor for urologic malignancy, as reported by the American Family Physician 5
• Microscopic hematuria is a risk factor for urologic malignancy, with a risk of up to 5% in patients with asymptomatic microscopic hematuria, according to the American Urological Association (AUA) 1

Follow-Up Recommendations

• The American Urological Association (AUA) recommends shared decision-making regarding additional evaluation if initial evaluation is negative but microscopic hematuria persists 1
• Further workup is warranted if the patient develops gross hematuria, significant increase in degree of microscopic hematuria, or new urologic symptoms after a negative evaluation, as recommended by the American Urological Association (AUA) 1

Important Caveats

• Early detection of urologic malignancy significantly impacts mortality and morbidity, and evaluation should not be delayed in high-risk patients, as stated by the American Urological Association (AUA) 1
• Urine dipstick testing should not be relied upon without microscopic confirmation, as recommended by the American Family Physician 3
• The risk of malignancy increases with the degree of hematuria (number of RBCs per HPF), according to the American Urological Association (AUA) 1

Urologic Evaluation with Cystoscopy and Upper Tract Imaging

Diagnostic Approach

• The presence of RBCs without casts in urinalysis suggests a non-glomerular (urologic) source rather than renal parenchymal disease, according to the American Academy of Family Physicians 6, 7
• The absence of casts and normal-appearing RBCs in urinalysis indicates a urologic source of hematuria, as suggested by the American Academy of Family Physicians 6, 7

Referral Guidelines

• Nephrology referral is not indicated in the absence of red cell casts, dysmorphic RBCs, significant proteinuria (>500-1000 mg/24 hours), or elevated serum creatinine, as recommended by the American Academy of Family Physicians 6, 7
• The American Academy of Family Physicians suggests that the presence of significant proteinuria (>500-1000 mg/24 hours) is an indication for nephrology referral 6

Diagnostic Evaluation of Hematuria in High-Risk Patients

Risk Stratification and Diagnostic Considerations

• The American College of Physicians recommends that patients with high-risk factors, such as age ≥60 years, be considered for complete urologic evaluation, as they are at increased risk for urologic malignancy 8
• Anticoagulation/antiplatelet therapy does not explain hematuria and may simply unmask underlying pathology, therefore evaluation must proceed regardless, as suggested by the American College of Physicians 8
• Voided urine cytology may be considered in high-risk patients, though not routinely recommended for all patients with microscopic hematuria, according to the American College of Physicians 8

Evaluation and Management of Hematuria

Introduction to Guideline Recommendations

• The American Urological Association (AUA) recommends that non-malignant urological conditions, such as non-obstructive nephrolithiasis, should not prevent a comprehensive evaluation of microscopic hematuria 9
• Patients with persistent microscopic hematuria and non-obstructive nephrolithiasis require a referral for a comprehensive urological evaluation, including cystoscopy and imaging of the upper urinary tract 9

Risk Stratification

• The decision to refer a patient depends on their risk category for urological malignancy, with factors such as age, smoking history, and occupational exposure to chemicals being considered 9
• Occupational exposure to chemicals, such as benzene and aromatic amines, is a risk factor for urological malignancy 10, 11
• A history of gross hematuria, irritative voiding symptoms, and degree of hematuria are also important factors in risk stratification 10, 11

Exclusion of Renal Parenchymal Disease

• Before referring a patient to urology, it is essential to exclude signs of glomerulonephropathy, such as significant proteinuria, hematuria with dysmorphic red blood cells, and elevated serum creatinine 10, 11
• Patients with significant proteinuria (>500-1000 mg/24h) require a referral to nephrology 10, 11

Guideline Recommendations

• The American Urological Association (AUA) recommends a comprehensive urological evaluation, including cystoscopy and imaging of the upper urinary tract, for patients with microscopic hematuria and non-obstructive nephrolithiasis 9
• Patients with high-risk factors for urological malignancy should be referred immediately for a comprehensive urological evaluation, including cystoscopy and CT urography 9